Biotech: Page 16
-
Q&A // Biotech Spotlight
Galecto has identified a master switch to reduce fibroid formation
With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.
By Taren Grom • Jan. 11, 2023 -
Biotech Spotlight
Chinook Therapeutics nears the finish line in kidney disease
A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.
By Michael Gibney • Jan. 10, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Making Moves
C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans
A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.
By Karissa Waddick • Jan. 10, 2023 -
Q&A // Biotech Spotlight
Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
By Taren Grom • Jan. 9, 2023 -
What’s top of mind for industry execs at JPM?
Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.
By Taren Grom • Jan. 6, 2023 -
Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023
As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.
By Michael Gibney • Jan. 5, 2023 -
Nonprofits are bridging R&D’s valley of death
How charitable firms such as Advancium are helping to right the market wrongs of drug development.
By Kelly Bilodeau • Jan. 4, 2023 -
Podcast
Woman of the Week: Cambrian BioPharma’s Juliette Han
The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.
By Taren Grom • Jan. 4, 2023 -
Opinion
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023 -
Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease
New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.
By Michael Gibney • Dec. 22, 2022 -
Podcast
Woman of the Week: Exelixis’ Dr. Vicki Goodman
With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.
By Taren Grom • Dec. 14, 2022 -
Tracker
The 2023 PharmaVoice Year in Preview
Here’s a look at how industry leaders are navigating the key issues of 2023.
Dec. 12, 2022 -
With FDA filing on the horizon, Karuna appoints new CEO
Allergan alum Bill Meury will take the helm as current CEO Steve Paul transitions to lead R&D.
By Karissa Waddick • Dec. 9, 2022 -
Q&A
For Duchenne-focused Sarepta, gene therapy is the natural next step
The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.
By Michael Gibney • Dec. 8, 2022 -
10 noteworthy pharma leadership shake-ups this year
From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.
By Karissa Waddick • Dec. 7, 2022 -
Podcast
Woman of the Week: Simcha Therapeutics’ Beatrice McQueen
From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.
By Taren Grom • Dec. 7, 2022 -
Q&A
A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’
The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug.
By Meagan Parrish • Dec. 6, 2022 -
Opinion
Healthcare tech’s biggest busts
The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.
By Taren Grom • Dec. 2, 2022 -
5 final FDA action dates to watch this year
A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.
By Michael Gibney • Dec. 1, 2022 -
10 of our most popular articles in 2022
Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.
By Meagan Parrish • Nov. 30, 2022 -
Podcast
Woman of the Week: Surface Oncology’s Dr. Alison O’Neill
With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.
By Taren Grom • Nov. 30, 2022 -
One biotech’s approach to science-driven innovation
Why some in the industry say fostering creativity in drug development is all about work structures.
By Karissa Waddick • Nov. 29, 2022 -
Q&A // Biotech Spotlight
Evommune’s unique method of drug discovery is more than skin deep
The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.
By Michael Gibney • Nov. 29, 2022 -
Avoiding a ‘bad trip’ in psychedelic clinical trials
Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.
By Kelly Bilodeau • Nov. 28, 2022 -
Podcast
Woman of the Week: Myriad Genetics’ Nicole Lambert
Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.
By Taren Grom • Nov. 23, 2022